Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Reports Lung Cancer Development In Some Exubera Users

Executive Summary

Primary lung malignancies have developed in several patients taking Pfizer's inhaled insulin Exubera, which it stopped marketing last fall, but the relationship between the adverse event and the drug remains unclear

You may also be interested in...



MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin

Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.

Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily

FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.

As Pfizer Closes Door On Exubera, Has Window Opened For Others?

Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer

Latest News
UsernamePublicRestriction

Register

PS049513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel